Broker Notes: Why analysts name Pro Medicus, Breville and Lynas to buy now?

$Pro Medicus Ltd(PME.AU)$: Wilsons is overweight on the stock with a A$51.00 target price.
Pro Medicus's announcement of two key contract renewals demonstrates that large U.S. customers are seeing a return on investment in the Australian medical-imaging firm's Visage 7 software, Wilsons analysts say in a note.

$Breville Group Ltd(BRG.AU)$: UBS lowers its target price by 26% to A$25.00 but maintains a buy rating on the stock.
Small-appliances maker Breville Group could pull back on some marketing and R&D costs if the deteriorating economic environment results in materially softer revenue, UBS says.

$Lynas Rare Earths Ltd(LYC.AU)$: Macquarie has an outperform rating and A$12.80 target price on the stock.
Lynas Rare Earths' contract with the U.S. Department of Defense could start heavy rare earth production a year earlier than anticipated by Macquarie's analysts.